What RapidAI and Optellum Announced About Lung Nodule AI on the Rapid Enterprise Platform
In an announcement dated 20 October 2026, carried on the RapidAI site and datelined Oxford and Houston, Optellum said its Virtual Nodule Clinic with Lung Cancer Prediction AI is now integrated with the Rapid Enterprise Platform from RapidAI. The announcement says the product joins a portfolio of more than 50 RapidAI and third-party clinical solutions and extends the platform into the lung nodule pathway, and that RapidAI technology is used in more than 2,500 hospitals across more than 100 countries. Optellum chief executive Johnathan Watkins is quoted saying the collaboration makes the Virtual Nodule Clinic available to the many health systems already using the platform. Optellum describes the product as the world's first FDA cleared and Medicare reimbursed AI solution for image-based lung cancer risk stratification, reimbursed under the codes 0721T and 0722T. On regulatory status, this site's own FDA directory carries Optellum, Ltd. clearance K202300 for the Optellum Virtual Nodule Clinic, decided 5 March 2021, filed under software that helps assess lesions suspicious for cancer.
Why the RapidAI and Optellum Integration Matters to Lung Cancer and Imaging Programmes
This one is more than a plumbing announcement because of what Optellum carries with it. A cleared product that also has billing codes behind it is unusual in imaging AI, and it means a hospital can argue for the tool on money as well as on care quality. Putting it on a platform that is already installed removes the slowest part, which is the IT project. The limit is what a risk score actually changes. Scoring a nodule only helps if a nodule clinic exists to act on the score, and most of the work is pulmonology, thoracic surgery and follow-up scheduling rather than radiology. The reimbursement claim is also the company's own framing, so a finance team should check what a real claim paid rather than what the code allows. The number worth asking for is how many scored patients reached a diagnosis sooner, not how many sites switched it on.
Where the RapidAI Update Comes From
RapidAI is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.
How We Would Research the RapidAI and Optellum Integration
The source gives us the starting point. This is how we would build the next layer of research around it.
- We would check the two billing codes against a real paid claim rather than the company description, because reimbursed can mean a code exists rather than a payer paid it.
- Then we would ask Optellum and RapidAI how many hospitals on the platform have actually turned the Virtual Nodule Clinic on, since availability and use are different numbers.
- We would ask a hospital running it who receives a high risk score and what happens next, because a lung nodule score only matters if a clinic acts on it.